3-chloro-4-mercapto-phenol | 42468-31-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 英文名称: 3-chloro-4-mercapto-phenol
• 英文别名: 3-Chlor-4-mercapto-phenol；2-Chloro-4-hydroxythiophenol；3-chloro-4-sulfanylphenol
• CAS: 42468-31-5
• 化学式: C₆H₅ClOS
• 分子量: 160.624
• InChiKey: NOVYXHUXXQVNMN-UHFFFAOYSA-N

物化性质

• 熔点：
  51-52 °C
• 沸点：
  135 °C(Press: 2 Torr)
• 密度：
  1.428±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  21.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-chloro-4-mercapto-phenol 在 sodium hydroxide 作用下， 生成 3-chloro-4-methylsulfanyl-phenol
  参考文献：
  名称：

  Acharya et al., Journal of the Karnatak University, 1958, vol. 3, p. 25,28, 30

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium acetate 作用下， 生成 3-chloro-4-mercapto-phenol
  参考文献：
  名称：

  Acharya et al., Journal of the Karnatak University, 1958, vol. 3, p. 25,28, 30

  摘要：

  DOI：

文献信息

• [EN] PROCESS FOR THE PREPARATION OF 1-ACYL-4-PHENYLSULFONYLPROLINAMIDE DERIVATIVES AND NEW INTERMEDIATES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS 1-ACYL-4-PHÉNYLSULFONYLPROLINAMIDE ET DE NOUVEAUX INTERMÉDIAIRES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013068434A1

  公开（公告）日：2013-05-16

  A novel process for the preparation of proline derivatives of formula (I) wherein,R1 is selected from C1-7-alkyl or from formula (II) wherein R4 is selected from C1-7-alkyl, halogen-C1-7-alkyl or from phenyl which is optionally substituted by halogen; R2 is selected from halogen or halogen-C1-7-alkyl; and R3 is selected from hydrogen, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy or from a 5- or 6-membered heterocyclic ring containing one or two nitrogen atoms, the ring which is optionally substituted by C1-7-alkyl or halogen is described. The proline derivatives of the formula I are preferential inhibitors of the cysteine protease Cathepsin S and are therefore useful to treat metabolic diseases like diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease and diabetic nephropathy.

  一种用于制备式(I)的脯氨酸衍生物的新型方法，其中，R1从C1-7-烷基或从式(II)中选择，其中R4从C1-7-烷基、卤代C1-7-烷基或从苯且可以被卤素取代中选择；R2从卤素或卤代C1-7-烷基中选择；R3从氢、卤素、卤代C1-7-烷基、C1-7-烷氧基、卤代C1-7-烷氧基或从含有一个或两个氮原子的5-或6-成员杂环环中选择，该环可以被C1-7-烷基或卤素取代。式(I)的脯氨酸衍生物是优选的半胱氨酸蛋白酶S的抑制剂，因此可用于治疗代谢性疾病，如糖尿病、动脉粥样硬化、腹主动脉瘤、外周动脉疾病和糖尿病肾病。
• [EN] NOVEL SUBSTITUTED ARYL COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS<br/>[FR] NOUVEAUX COMPOSES D'ARYLE SUBSTITUES UTILES COMME MODULATEURS DES RECEPTEURS DE L'ACETYLCHOLINE
  申请人：SIBIA NEUROSCIENCES, INC.

  公开号：WO1997019059A1

  公开（公告）日：1997-05-29

  (EN) In accordance with the present invention, a novel class of substituted aryl compounds (containing ether, ester, amide, ketone or thioether substitution) that promote the release of ligands involved in neurotransmission have been discovered. In a particular aspect, compounds of the present invention are capable of modulating acetylcholine receptors. The compounds of the present invention are capable of displacing one or more acetylcholine receptor ligands, e.g., 3H-nicotine, from mammalian neuronal membrane binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors. Therapeutic indications for compounds with activity at acetylcholine receptors include diseases of the central nervous system such as Alzheimer's disease and other diseases involving memory loss and/or dementia (including AIDS dementia); cognitive dysfunction (including disorders of attention, focus and concentration), disorders of extrapyramidal motor function such as Parkinson's disease, progressive supramuscular palsy, Huntington's disease, Gilles de la Tourette syndrome and tardive dyskinesia; mood and emotional disorders such as depression, anxiety and psychosis; substance abuse including withdrawal symptoms and substitution therapy; neurocrine disorders and dysregulation of food intake, including bulimia and anorexia; disorders or nociception and control of pain; autonomic disorders including dysfunction of gastrointestinal motility and function such as inflammatory bowel disease, irritable bowel syndrome, diarrhea, constipation, gastric acid secretion and ulcers; pheochromocytoma, cardiovascular dysfunction including hypertension and cardiac arrhythmias, as well as co-medication uses in surgical applications.(FR) Selon la présente invention, il a été découvert une nouvelle classe de composés d'aryle substitués (contenant une substitution éther, ester, amide, cétone ou thioéther) qui favorisent la libération de ligands impliqués dans la neurotransmission. Dans un aspect particulier, ces composés sont capables de moduler les récepteurs de l'acétylcholine, ainsi que de déplacer un ou plusieurs ligands des récepteurs de l'acétylcholine, tels que la 3H-nicotine, des sites de liaison de la membrane des neurones chez les mammifères. Ils peuvent se comporter comme des agonistes, des agonistes partiels, des antagonistes ou des modulateurs allostériques des récepteurs de l'acétylcholine. Les indications thérapeutiques des composés ayant une activité sur les récepteurs de l'acétylcholine sont les suivantes: les maladies du système nerveux central comme la maladie d'Alzheimer et d'autres pathologies accompagnées d'une perte de mémoire et/ou d'une démence (y compris la démence du sida); les troubles cognitifs (troubles de l'attention et de la concentration), les troubles de la fonction motrice extra-pyramidale comme la maladie de Parkinson, la paralysie supramusculaire progressive, la maladie de Huntington, le syndrome de Gilles de la Tourette et la dyskinésie tardive; les troubles de l'humeur et les troubles émotionnels tels que la dépression, l'angoisse et la psychose; les toxicomanies, y compris les symptômes de manque et la thérapie de substitution; les troubles endocriniens et la dysrégulation de la prise alimentaire, y compris la boulimie et l'anorexie; les troubles de la nociception et la lutte contre la douleur; les perturbations du système nerveux autonome telles que les troubles de la motilité et du fonctionnement gastro-intestinal, notamment les maladies intestinales inflammatoires, le syndrome de l'intestin irritable, la diarrhée, la constipation, l'hypersécrétion d'acide gastrique et les ulcères; le phéochromocytome, les troubles cardio-vasculaires y compris l'hypertension et les arythmies cardiaques. Ces composés peuvent également être utilisés en tant que co-médication en chirurgie.

  根据本发明，发现了一类新型的取代芳基化合物（包含醚，酯，酰胺，酮或硫醚取代），可促进神经递质中涉及的配体的释放。在特定方面，本发明的化合物能够调节乙酰胆碱受体。本发明的化合物能够从哺乳动物神经元膜结合位点中取代一个或多个乙酰胆碱受体配体，例如3H-尼古丁。发明化合物可以作为乙酰胆碱受体的激动剂，部分激动剂，拮抗剂或别构调节剂。具有对乙酰胆碱受体活性的化合物的治疗适应症包括中枢神经系统疾病，如阿尔茨海默病和其他涉及记忆丧失和/或痴呆的疾病（包括艾滋病痴呆）; 认知功能障碍（包括注意力，专注力和集中力障碍），运动功能异常如帕金森病，进行性肌肉萎缩性侧索硬化症，亨廷顿病，吉尔斯·德·拉·图雷特综合症和迟发性运动障碍; 心境和情感障碍，如抑郁症，焦虑和精神病; 物质滥用，包括戒断症状和替代疗法; 神经内分泌障碍和食物摄入的失调，包括暴食症和厌食症; 疼痛的感觉和控制障碍; 自主神经障碍，包括胃肠运动和功能障碍，如炎症性肠病，肠易激综合症，腹泻，便秘，胃酸分泌和溃疡; 嗜铬细胞瘤，心血管功能障碍，包括高血压和心律失常，以及在手术应用中的联用用途。
• [EN] AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS<br/>[FR] COMPOSES AZACYCLIQUES EN TANT QUE MODULATEURS DE RECEPTEURS D'ACETYLCHOLINE
  申请人：LILLY CO ELI

  公开号：WO2003062224A1

  公开（公告）日：2003-07-31

  Compounds comprising an aza-cyclic portion and an aromatic portion linked via a sulphur atom are disclosed. The compounds disclosed are selective modulators of beta 4 subtype nicotinic acetylcholine receptors and are useful for the treatment of dysfunctions of the central and autonomic nervous systems.

  本发明揭示了一种由一个氮杂环部分和一个芳香部分通过硫原子连接的化合物。所揭示的化合物是选择性调节β4亚型尼古丁酰胆碱受体的调节剂，并可用于治疗中枢神经系统和自主神经系统的功能障碍。
• Modulators of acetylcholine receptors
  申请人：Astles Charles Peter

  公开号：US20050182088A1

  公开（公告）日：2005-08-18

  The present invention relates to compounds that modulate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine. More particularly, the present invention relates to thio-bridged aryl compounds that are capable of modulating acetylcholine receptors and pharmaceutical compositions comprising such compounds. The compounds disclosed are useful for the treatment of dysfunctions of the central and autonomic nervous systems.

  本发明涉及化合物，通过促进乙酰胆碱、多巴胺和去甲肾上腺素等神经递质的释放来调节神经递质。更具体地，本发明涉及能够调节乙酰胆碱受体的硫桥联芳基化合物和包含此类化合物的药物组合物。所披露的化合物对中枢神经系统和自主神经系统功能障碍的治疗具有用处。
• Substituted aryl compounds useful as modulators of acetylcholine receptors
  申请人：Merck & Co., Inc.

  公开号：US06316490B1

  公开（公告）日：2001-11-13

  In accordance with the present invention, a novel class of substituted aryl compounds (containing ether, ester, amide, ketone or thioether substitution) that promote the release of ligands involved in neurotransmission have been discovered. In a particular aspect, compounds of the present invention are capable of modulating acetylcholine receptors. The compounds of the present invention are capable of displacing one or more acetylcholine receptor ligands, e.g., 3H-nicotine, from mammalian neuronal membrane binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors. Therapeutic indications for compounds with activity as acetylcholine receptors include diseases of the central nervous system such as Alzheimer's disease and other diseases involving memory loss and/or dementia (including AIDS dementia); cognitive dysfunction (including disorders of attention, focus and concentration), disorders of extrapyramidal motor function such as Parkinson's disease, progressive supramuscular palsy, Huntington's disease, Gilles de la Tourette syndrome and tardive dyskinesia; mood and emotional disorders such as depression, anxiety and psychosis; substance abuse including withdrawal symptoms and substitution therapy; neurocrine disorders and dysregulation of food intake, including bulimia and anorexia; disorders of nociception and control of pain; autonomic disorders including dysfimction of gastrointestinal motility and function such as inflammatory bowel disease, irritable bowel syndrome, diarrhea, constipation, gastric acid secretion and ulcers; pheochromocytoma, cardiovascular dysfunction including hypertension and cardiac arrhythmias, as well as co-medication uses in surgical applications.

  根据本发明，发现了一类新型的取代芳基化合物（包含醚、酯、酰胺、酮或硫醚取代），能促进神经递质中涉及的配体的释放。在一个特定的方面，本发明的化合物能够调节乙酰胆碱受体。本发明的化合物能够从哺乳动物神经元膜结合位点中取代一个或多个乙酰胆碱受体配体，例如3H-尼古丁。发明化合物可以作为乙酰胆碱受体的激动剂、部分激动剂、拮抗剂或变构调节剂。具有作为乙酰胆碱受体活性的化合物的治疗适应症包括中枢神经系统疾病，如阿尔茨海默病和其他涉及记忆丧失和/或痴呆的疾病（包括艾滋病痴呆）；认知功能障碍（包括注意力、焦点和集中障碍）；外周运动功能障碍，如帕金森病、进行性肌萎缩性侧索硬化症、亨廷顿病、吉尔斯·德·拉·图雷特综合征和迟发性运动障碍；情绪和情感障碍，如抑郁症、焦虑和精神病；物质滥用，包括戒断症状和替代疗法；神经内分泌障碍和食物摄入调节失调，包括暴食症和厌食症；疼痛感知和控制障碍；自主神经障碍，包括胃肠道运动和功能障碍，如炎症性肠病、肠易激综合征、腹泻、便秘、胃酸分泌和溃疡；嗜铬细胞瘤、心血管功能障碍，包括高血压和心律失常，以及在外科应用中的联合用药。